Literature DB >> 7023893

Efficacy of clonidine in opiate withdrawal: a study of thirty patients.

M S Gold, A L Pottash, D R Sweeney, H D Kleber.   

Abstract

In a placebo-controlled, double-blind crossover trial, clonidine caused a marked and significant reduction of objective signs and subjective symptoms of opiate withdrawal in thirty hospitalized opiate addicts. In an open trial of clonidine in opiate withdrawal, clonidine was found to suppress opiate withdrawal signs and symptoms, allowing all of the patients to detoxify successfully from chronic opiate addiction. Clonidine was demonstrated to reverse and suppress the signs, symptoms, and effects associated with opiate withdrawal. These data support a release from chronic opiate-induced noradrenergic inhibition producing noradrenergic hyperactivity as the pathophysiological substrate for opiate withdrawal. Clonidine replaces opiate-mediated inhibition with alpha-2 mediated inhibition of noradrenergic nuclei.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7023893     DOI: 10.1016/0376-8716(80)90323-3

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  8 in total

Review 1.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

2.  The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers.

Authors:  Ziva D Cooper; Kirk W Johnson; Martina Pavlicova; Andrew Glass; Suzanne K Vosburg; Maria A Sullivan; Jeanne M Manubay; Diana M Martinez; Jermaine D Jones; Phillip A Saccone; Sandra D Comer
Journal:  Addict Biol       Date:  2015-05-14       Impact factor: 4.280

Review 3.  κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction.

Authors:  Eduardo R Butelman; Vadim Yuferov; Mary Jeanne Kreek
Journal:  Trends Neurosci       Date:  2012-06-16       Impact factor: 13.837

4.  Oral clonidine pretreatment prior to venous cannulation.

Authors:  David L Hall; Ehsan Rezvan; Dimitris N Tatakis; John D Walters
Journal:  Anesth Prog       Date:  2006

Review 5.  The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol.

Authors:  Thomas M Tzschentke; Thomas Christoph; Babette Y Kögel
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

6.  Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.

Authors:  Matisyahu Shulman; Tse-Hwei Choo; Jennifer Scodes; Martina Pavlicova; Jonathan Wai; Patrick Haenlein; Babak Tofighi; Aimee N C Campbell; Joshua D Lee; John Rotrosen; Edward V Nunes
Journal:  J Subst Abuse Treat       Date:  2021-01-16

7.  Amantadine as Augmentation in Managing Opioid Withdrawal with Clonidine: a randomized controlled trial.

Authors:  Shahrokh Amiri; Ayyoub Malek; Farid Tofighnia; Bohlool Habibi Asl; Ali Seidy
Journal:  Iran J Psychiatry       Date:  2014-07

8.  The therapeutic effect of adding dextromethorphan to clonidine for reducing symptoms of opioid withdrawal: a randomized clinical trial.

Authors:  Ayyoub Malek; Shahrokh Amiri; Bohlool Habibi Asl
Journal:  ISRN Psychiatry       Date:  2013-06-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.